Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by AngelMan92on Jan 25, 2021 2:02pm
234 Views
Post# 32377135

Greetings From an Angel

Greetings From an Angel

Hi,

I'd like to say I feel vindicated. I like Tripp and fingers crossed I can retire off this hahahh

I was nervous a little bit there, not because I doubted the company, but because this isnt the only company I am interested in and I thought it would blow sooner. That being said, it's time for the good stuff.

Tripp has estimated global revenue for Aristotle at $2 billion, I am guessing that's for a few years from now. What really interested me is him announcing ARISTOTLE 2, which will focus on cardiovascular and neurodegenerative disease... this man is really smart to be targetting these fields that are not nearly perfected yet. To me this means that this company really has the skys limit of market cap, but will realistically hit 1 billion market cap as long as profitability trajections are as good as he implies.

Happy New Year to All, particularly those I remember like Nailz, CapeBretonGirl, and Johnny to name the ones off the top of my head. Best of luck to all, and let's make money :))

<< Previous
Bullboard Posts
Next >>